Gregor Hasler

Gregor Hasler is a Full Professor in the Department of Medicine at the University of Fribourg, within the Faculty of Mathematics, Natural Sciences and Medicine. He leads a dynamic research group focused on molecular neuroimaging and novel treatments for affective disorders, including depression and bipolar disorder. His work bridges clinical psychiatry, neuroscience, and public health, with a strong emphasis on translational research.

His research interests include:

• Glutamate and GABA neurotransmitter systems in mood disorders
• Ketamine and psychedelic (e.g., LSD) therapies for depression
• Neuroplasticity and brain circuitry in psychiatric illness
• The gut-brain axis and its role in mental health
• Biomarker development for depression, addiction, and schizophrenia
• Social behavior and competition avoidance in depression
• Resilience and psychosocial factors in stress-related disorders

The most recent publications from Prof. Hasler’s group reflect a strong trend toward multimodal neuroimaging (MRI, fMRI, PET, MRS) to understand the neurochemical basis of psychiatric disorders. There is a growing focus on rapid-acting antidepressants like ketamine and psychedelics, with an emphasis on neuroplasticity and treatment personalization through biomarkers. Research also explores social and behavioral dimensions of depression, integrating psychology, economics, and neuroscience. The gut-brain axis is increasingly prominent, linking microbiome, immunity, and neural function in mental illness.

While no specific scientific awards are mentioned in the provided text, Prof. Hasler has made significant contributions through high-impact research and public engagement. He has authored influential books for the general public and is frequently invited to speak at national and international events.

Prof. Hasler actively mentors students and early-career researchers, including doctoral candidates such as Abigail Elizabeth Calder, Adrian Hase, Claudia Kolly, and Yoan Mihov. His research is supported by collaborations with institutions like the University of Zurich and the Mount Sinai School of Medicine. He is involved in clinical trials and public health initiatives, including the evaluation of anti-stigma campaigns and the implementation of novel therapies in outpatient settings.

He leads the Hasler Research Group, which investigates:

• Molecular mechanisms of depression and bipolar disorder
• Clinical applications of ketamine and psychedelics
• Neural and behavioral correlates of social dysfunction
• Epigenetic and metabolic biomarkers
• Therapeutic modulation of the gut-brain axis